
Carbapenem-resistant Enterobacterales (CRE) are a significant concern in clinical microbiology, but does carbapenem resistance always mean an organism produces a carbapenemase? And why is identifying the specific resistance mechanism so important?
In this episode of Let's Talk Micro, Dr. Hannah Creager and Dr. Erin McCreary return to discuss carbapenemase testing and its implications for laboratory workflows and patient care. They explore the different mechanisms that can lead to carbapenem resistance, the changing landscape of carbapenemases such as KPC and NDM, and the importance of identifying specific enzymes to help guide antimicrobial therapy.
The conversation also covers phenotypic and genotypic testing methods, recommendations for carbapenemase testing, and practical considerations for implementing testing workflows. Drawing from their experience at UPMC, Hannah and Erin discuss how collaboration between clinical microbiology, antimicrobial stewardship, infectious diseases, and infection prevention can help translate laboratory results into actionable information for patient care.
Guests:
-
Hannah Creager, PhD — University of Pittsburgh Medical Center (UPMC)
-
Erin McCreary, PharmD — University of Pittsburgh Medical Center (UPMC)
Sponsorship and Disclosures
This episode is sponsored by CorMedix Therapeutics.
Disclosures: Erin McCreary has served as a consultant for CorMedix, Shionogi, bioMerieux, Meitheal, Wockhardt, Beckman Coulter, and GSK. Hannah Creager has nothing to disclose.
The views and opinions expressed are those of the speakers and do not necessarily reflect the views of CorMedix.
Stay connected with Let's Talk Micro:
-
Website: letstalkmicro.com
-
Questions or feedback? Email me at [email protected]
-
Interested in being a guest on Let's Talk Micro? Fill out the form here: https://forms.gle/V2fT3asjfyusmqyi8
Support the podcast:
Altri episodi di "Let's Talk Micro"



Non perdere nemmeno un episodio di “Let's Talk Micro”. Iscriviti all'app gratuita GetPodcast.








